Use of nonsteroidal anti-inflammatory drugs and risk of fractures

被引:45
|
作者
Van Staa, TP
Leufkens, HGM
Cooper, C
机构
[1] Univ Utrecht, Dept Pharmacoepidemiol & Pharmacotherapy, Utrecht, Netherlands
[2] Southampton Univ Hosp, MRC, Environm Epidemiol Unit, Southampton, Hants, England
关键词
prostaglandin; osteoporosis; NSAIDs;
D O I
10.1016/S8756-3282(00)00361-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In animal models, prostaglandin synthesis has been found to mediate bone metabolism. Nonsteroidal anti-inflammatory drugs (NSAIDs), given their inhibitory effects of prostaglandin synthesis, may play a role in the prevention of osteoporosis. The primary objective of this study is to describe and quantify the fracture risks of patients exposed to NSAIDs in a representative general medical practice setting. A retrospective cohort study was conducted in a general medical practice setting in the UK (using data from the General Practice Research Database). Regular NSAID users (who received three or more NSAID prescriptions), aged 18 years or older, were compared with matched control patients and incidental NSAID users. The study comprised 214,577 regular NSAID users, 286,850 incidental NSAID users, and 214,577 control patients. The relative rate of nonvertebral fractures during regular NSAID treatment compared with control was 1.47 (95% confidence interval [CI] 1.42-1.52) and that of hip fracture 1.08 (0.98-1.19); No differences in nonvertebral fractures were found between the regular and incidental NSAID users (RR = 1.04; 95% CI 0.99-1.09), The rate of nonvertebral fractures among users of diclofenac (RR = 1.00; 95% CI 0.93-1.08) and naproxen (RR = 0.91; 95% CI 0.82-1.00) was similar to that of ibuprofen, The results of this study are not supportive of clinically significant effects of NSAIDs on bone metabolism. (Bone 27:563-568; 2000) (C) 2000 by Elsevier Science Inc. All rights reserved.
引用
收藏
页码:563 / 568
页数:6
相关论文
共 50 条
  • [11] Nonsteroidal anti-inflammatory drugs
    Gotzsche, PC
    AMERICAN FAMILY PHYSICIAN, 2006, 73 (03) : 507 - 508
  • [12] Nonsteroidal anti-inflammatory drugs
    Tseng, CC
    Wolfe, MM
    MEDICAL CLINICS OF NORTH AMERICA, 2000, 84 (05) : 1329 - +
  • [13] Nonsteroidal anti-inflammatory drugs
    Moses, VS
    Bertone, AL
    VETERINARY CLINICS OF NORTH AMERICA-EQUINE PRACTICE, 2002, 18 (01) : 21 - +
  • [14] Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs
    Hermann M.
    Current Rheumatology Reports, 2009, 11 (1) : 31 - 35
  • [15] Nonsteroidal anti-inflammatory drugs and prostate cancer risk
    Christine Kyme
    Nature Clinical Practice Urology, 2005, 2 (9): : 410 - 411
  • [16] Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease
    Chen, HL
    Zhang, SMM
    Hernán, MA
    Schwarzschild, MA
    Willett, WC
    Colditz, GA
    Speizer, FE
    Ascherio, A
    ARCHIVES OF NEUROLOGY, 2003, 60 (08) : 1059 - 1064
  • [17] Nonsteroidal anti-inflammatory drugs and the risk of hidradenitis suppurativa
    Clerbout, Marianne
    Chavrier, Christelle
    Beuque, Marianne
    Gaspard, Samantha
    Evain, Ines
    Fioretta, Myriam
    Enault, Christelle
    Math, Sylvia
    Gadat, Anne-Sophie
    Vlaeminck-Guillem, Virginie
    Guillem, Philippe
    EXPERIMENTAL DERMATOLOGY, 2023, 32 : 130 - 131
  • [18] Nonsteroidal anti-inflammatory drugs and the risk of skin cancer
    Johannesdottir, Sigrun Alba
    Chang, Ellen T.
    Mehnert, Frank
    Schmidt, Morten
    Olesen, Anne Braae
    Sorensen, Henrik Toft
    CANCER, 2012, 118 (19) : 4768 - 4776
  • [19] Nonsteroidal anti-inflammatory drugs and risk of lung cancer
    Hernandez-Diaz, Sonia
    Garcia Rodriguez, Luis A.
    INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (07) : 1565 - 1572
  • [20] Cardiovascular effects and the use of nonsteroidal anti-inflammatory drugs
    Schellack, N.
    SOUTH AFRICAN FAMILY PRACTICE, 2014, 56 (01) : 16 - 20